SuperworthOnconetix ONCO
- Market cap
- $1.7M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Onconetix's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | $700.4K | $704.8K | $406.9K | n/a | $101.6K−86% | $106.5K−85% | $303.7K−25% | n/a | $21.5K−79% | $17.1K−84% | |
| Cost of revenue | n/a | n/a | $511.4K | $604.1K | $301.4K | n/a | $55.8K−89% | $36K−94% | $34.8K−89% | n/a | $23.1K−59% | $12.8K−64% |
| Gross profit | n/a | n/a | $189K | $100.7K | $105.4K | n/a | $45.8K−76% | $70.5K−30% | $268.9K+155% | n/a | −$1.7K | $4.3K−94% |
| R&D | $219.2K−81% | n/a | $49K−96% | −$3.7K | $109.4K−50% | n/a | $24.5K−50% | −$111.7K+2935% | −$3.2K | n/a | $50.8K+108% | $3.4K |
| SG&A | $4.3M+58% | n/a | $3.7M+112% | $2.2M−4% | $2.6M−38% | n/a | $1.7M−55% | $1.5M−31% | $2.3M−11% | n/a | $2M+22% | $2.2M+47% |
| −$4.5M+16% | n/a | −$11.1M+289% | −$13.6M+105% | −$2.6M−41% | n/a | −$12.6M+13% | −$1.9M−86% | −$2.1M−22% | n/a | −$10.2M−19% | −$2.7M+41% | |
| Interest expense | $269.1K | $188.5K | $188K | $205.1K−4% | $231.7K−14% | n/a | $223.6K+19% | $223.1K+9% | $300.1K+30% | n/a | $2.2K−99% | $4.4K−98% |
| Pre-tax income | −$5.3M | n/a | −$11.2M+295% | −$14.3M+108% | −$3.9M−27% | n/a | −$8.5M−24% | −$2.4M−83% | −$8.8M+126% | n/a | −$4.2M−51% | −$2.9M+21% |
| n/a | n/a | −$121.6K | $50.8K | −$56.4K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$5.3M+38% | −$22.4M+595% | −$11.1M+291% | −$14.3M+108% | −$3.8M−28% | −$29.4M+32% | −$8.5M−23% | −$2.4M−83% | −$8.8M+130% | $5.7M | −$4.2M−51% | −$2.9M+21% |
| −$51892.50+13% | −$199282.50+486% | −$85340.00+179% | −$109579.50+50% | −$12454.00−76% | n/a | −$2272.50−97% | −$237.91−100% | −$312.50−98% | $181.50 | −$67.10−97% | −$1.28−100% | |
| 103+22% | 112+18% | 130+39% | 131+40% | 307+198% | n/a | 4.3K+3182% | 11.4K+8596% | 28.1K+9047% | 31.2K | 62.9K+1370% | 2.2M+19655% |
EPS, diluted: 12 periods, Q1 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q4 FY21 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Onconetix's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ONCOOnconetix | $1.7M | n/m | n/a | n/m | n/m | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $7.7M | 47.5× | 9.6× | 2.8× | +40% | 4.7% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| GTIMGood Times Restaurants | $13.6M | 6.1× | 13.6× | 0.1× | −6% | 1.7% | |
| MDRRMedalist Diversified | $15.4M | 2.5× | 3.0× | 1.6× | −1% | 80.2% | |
| Peer median | $11.2M | 5.8× | 10.5× | 1.0× | −3% | 6.7% |
More on Onconetix
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .